Study Of An Investigational Drug To Reduce Tumors In Children With Advanced Cancer
Seeking people aged 1-21 years old with certain kinds of solid tumor cancer for a study of an investigational drug.
Seeking people aged 1-21 years old with certain kinds of solid tumor cancer for a study of an investigational drug.
Seeking men and women with advanced relapsed, refractory, or resistant hematological (blood) cancer with an IDH mutation that has not responded or stopped responding to prior treatment for participation in a study of an investigational drug.
Seeking men and women who have been diagnosed since January 1, 2020, with metastatic non-small cell lung cancer and have been or will be treated with immunotherapy, chemotherapy or a combination of the two for a study to develop a tool to help guide treatment decisions.
Seeking men and women whose multiple myeloma has returned or gotten worse despite treatment for a study comparing investigational drug combinations.
Seeking men and women whose multiple myeloma has returned following treatment or did not respond to treatment for a study of an investigational drug.
Seeking men and women whose non-small cell lung cancer (NSCLC) has spread outside the lungs, and has a change in the gene called EGFR (epidermal growth factor receptor) and has not yet been treated for a study of an investigational drug combination.